In Brief: Tavist-D for colds
This article was originally published in The Tan Sheet
Tavist-D for colds: TV advertising for Sandoz' OTC clemastine fumerate allergy medication touts the recent recommendation by FDA's Nonprescription and Pulmonary-Allergy Drugs Advisory Committees that the ingredient be approved for the treatment of the common cold. FDA has not approved a cold indication for Tavist-D and Sandoz did not have an NDA on file when the recommendation was made ("The Tan Sheet" Nov. 20, p. 5). Sandoz issued a press release Feb. 21 announcing that "for the first time, two well-controlled clinical studies have proven that an antihistamine significantly reduces cold symptoms." The release, handled by Publicis Public Relations, Dallas, also mentions the advisory committee recommendation, noting that "clemastine fumerate is the only 12-hour antihistamine proven cold-effective"...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC